Alopecia Areata Treatment & ManagementAlopecia areata AA is a type of autoimmune disease characterized by hair loss that has a variable presentation and course. Some patients exhibit spontaneous remission, while others progress to develop total loss of scalp and body hair. The current therapy for AA is not curative, but rather aimed at controlling or limiting the pathogenic process. Their use was first described inwith the use of hydrocortisone. Steroids with low solubility are preferred for their slow tren e dosage from the injection site, promoting maximum intralesional kenalog for alopecia areata action with minimal systemic effect. Immunosuppression is the main areaha of action.
Intralesional Steroids in the Treatment of Alopecia Areata | Smart Patients
This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2. After the 1st 6 months, nonresponders or partial responders may be treated for 6 months with open label triamcinolone at the dose deemed appropriate by the investigator.
Injections will be performed at baseline, weeks 4, 8, 12, 16 and Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders. Trial information was received from ClinicalTrials. Report a problem with this trial page. Ask about this trial If you are interested in this trial, why not ask for more information?
Ask my doctor Ask the trial team. Trial Details overview summary locations study design arms eligibility additional information. Several images are licensed under the Creative Commons license. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20 intralesional triamcinolone 2. Proportion of responders time frame: Up to 48 weeks. Number of Adverse Events time frame: Alopecia areata AA is a major medical problem and is the most prevalent autoimmune disease in the US.
AA represents the second most common form of hair loss and causes significant disfigurement and psychological distress to affected individuals. AA affects more individuals than most other autoimmune diseases combined, including lupus erythematosus, type 1 diabetes, psoriasis, multiple sclerosis and rheumatoid arthritis.
In contrast to these conditions, research into the pathogenesis and the development of innovative therapies in AA has lagged behind. Alopecia areata is a common form of hair loss which reportedly occurs in up to 1. Alopecia areata is apparently triggered when the individual's own immune system attacks hair follicles on the scalp or body resulting in hair loss ranging from single patches on the scalp patch type alopecia areata to loss of every hair on the scalp and body alopecia universalis.
Currently, there are limited treatment options for alopecia areata and unfortunately, the treatments utilized have never been rigorously tested in a placebo controlled trial.
Triamcinolone Kenalog is a steroid solution that has been used as a treatment for alopecia areata for over 50 years. It is administered via injection into the scalp and appears to have some efficacy for patients with mild to moderate alopecia areata. The investigators currently do not have objective data on the frequency of occurrence of successful regrowth, the duration of response or the incidence of side effects.
Despite this, there are no adequately powered, randomized controlled clinical trials RCTs examining the efficacy, safety, and duration of effect of IL TAC.
In addition, the dosage or strength used varies among practitioners and the efficacy and safety of alternate doses of IL TAC has never been examined in a well designed RCT. Quantitative biomarkers for AA are a crucial step toward translational research aimed at clinical trials in AA.